13.08.2012 - Phase III results of Roche's unit Genentech Inc. show that a combination therapy including Avastin can significantly extend progression-free survival of patients with glioblastoma.
The AVAglio study investigating Avastin (bevacizumab) plus radiation and temozolomide chemotherapy (Merck's Temodar) in newly diagnosed brain tumour patients has met its co-primary endpoint of a significant improvement in progression-free survival compared with radiation and temozolomide chemotherapy alone. No new safety findings were observed in, and adverse events were consistent with those seen in previous trials of Avastin across its approved tumour types.
Data for the co-primary endpoint of overall survival are expected in 2013. The double-blind, international trial enrolled 921 patients. Basel-headquartered Roche and Genentech plan to discuss the results with EMA, FDA and other global regulatory authorities.
Avastin is currently approved in the US for adults with glioblastoma who have progressive disease following prior therapy and is only licensed for use as a single therapy and not in combination with other treatments. The product is not approved for glioblastoma in Europe.
17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.
11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.
09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.
08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.
The LiposoFast-Basic produces unilamellar liposomes by the manual extrusion of a multilamellar liposome suspension through a polycarbonate membrane of defined pore size, using gas-tight, glass syringes. more